Gilead Sciences | GILD - Interest Expense On Debt


Gilead Sciences reported $240M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
ALKERMES USD 20.89M 8.62M Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amgen USD 657M 4M Mar/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Bristol-Myers Squibb USD 411M 21M Mar/2026
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Incyte USD 569K 13K Mar/2026
J&J USD 43M 25M Mar/2026
Merck USD 479M 67M Mar/2026
Moderna USD 11.49B 36B Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 343M 39M Mar/2026
Pfizer USD 671M 40M Mar/2026
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR 178M 203M Mar/2026
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
United Therapeutics USD 3.1M 100K Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025